US 12,280,078 B2
Modified microorganisms expressing saga and related compositions for immunomodulation against infection and cancer immunotherapy
Howard Hang, Del Mar, CA (US); and Matthew Griffin, New York, NY (US)
Assigned to THE ROCKEFELLER UNIVERSITY, New York, NY (US)
Appl. No. 17/432,500
Filed by THE ROCKEFELLER UNIVERSITY, New York, NY (US)
PCT Filed Feb. 20, 2020, PCT No. PCT/US2020/019038
§ 371(c)(1), (2) Date Aug. 20, 2021,
PCT Pub. No. WO2020/172406, PCT Pub. Date Aug. 27, 2020.
Claims priority of provisional application 62/807,830, filed on Feb. 20, 2019.
Prior Publication US 2022/0168364 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/747 (2015.01); A23C 9/123 (2006.01); A23K 10/18 (2016.01); A23L 33/135 (2016.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/315 (2006.01); C12N 9/14 (2006.01)
CPC A61K 35/747 (2013.01) [A23C 9/1234 (2013.01); A23K 10/18 (2016.05); A23L 33/135 (2016.08); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/315 (2013.01); A23V 2002/00 (2013.01); A23V 2400/157 (2023.08); A23V 2400/169 (2023.08)] 7 Claims
 
1. Modified bacteria comprising that express a heterologous secreted antigen A (SagA) or an ortholog of SagA, said heterologous SagA having at least 80% sequence identity to SEQ ID NO: 1 and said ortholog having a NlpC/p60 hydrolase domain having at least 80% sequence identity to SEQ ID NO: 19, wherein the modified bacteria are Lactococcus lactis.